JLE

Médecine de la Reproduction

MENU

Préservation de la fertilité dans le cancer du sein : une vue oncologique Volume 16, issue 4, Octobre-Novembre-Décembre 2014

Figures


  • Figure 1

  • Figure 2

  • Figure 3

Tables

Authors
1 Gynecologic oncology and breast pathology section,
department of obstetrics, gynecology and reproduction,
Hospital Universitari Quirón-Dexeus,
C/Gran Via Carles III,
71-75,
08028 Barcelona,
Spain
2 Service of reproductive medicine,
department of obstetrics, gynecology and reproduction,
Hospital Universitari Quirón-Dexeus,
C/Gran Via Carles III,
71-75,
08028 Barcelona,
Spain
* Reprint.

The incidence of breast cancer has progressively increased, and around 15% of women are diagnosed before the age of 45. This subgroup of patients usually have more aggressive tumors and will receive additional systemic therapy (either chemotherapy, hormone therapy or both). Moreover, the tendency to delay childbearing age implies that a large proportion of young breast cancer patients have not completed their reproductive desire. The impact of the oncological treatment on the ovarian reserve depends on the age of the patients, the type of regimen given and the dose. Patient's oncologist must be concerned with the question of fertility and a prompt referral to reproductive counseling unit should be done. Controversy still exists about whether a delay on the onset of oncological treatment for fertility preservation can be accepted or not. In our center, 26 patients underwent oocyte cryopreservation between 2007-2012. The oocyte cryopreservation (ovarian stimulation and oocyte retrieval) took a minimum of two to three week, and the whole process (from pathological breast cancer diagnosis to the start of cancer treatment) took a mean of four weeks. We consider young patients should be referred to a reproductive counselling unit as fertility preservation can be done without causing a significant delay in the onset of oncological treatment. Fertility preservation is a multidisciplinary field that requires the participation of both the oncology team and human reproduction team.